Important announcements in Hong Kong stocks today:

1) Company News

$SENSETIME-W (00020.HK)$ Completed the restructuring of the strategic organizational structure, the company has established a new "1+X" framework to better respond to the opportunities and challenges brought by the AI 2.0 era.

$YUEXIU PROPERTY (00123.HK)$In the first 11 months, the cumulative contract sales amounted to 101.02 billion yuan, a decrease of about 24% year-on-year, accounting for 68.7% of the annual sales target.

$AGILE GROUP (03383.HK)$In the first 11 months, the cumulative contract sales amounted to 14.75 billion yuan, a decrease of 64.81% year-on-year.

$ZIJIN MINING (02899.HK)$The delivery of Peru's La Arena gold mine and Phase 2 project has been completed. As of June 30, 2024, the La Arena gold mine has confirmed and probable ore reserves totaling 22.6 million tons, with approximately 8 tons of gold, and an average grade of 0.33 grams per ton.

$MMG (01208.HK)$The main changes in the declared mineral resources and ore reserves as of June 30, 2024 are as follows: copper increased by 17%, zinc increased by 14%, lead increased by 10%, molybdenum increased by 62%, cobalt increased by 10%, silver increased by 11%, gold increased by 5%, and non-metal decreased.

$FANGZHOU JIANKE (06086.HK)$Included in the hang seng hong kong-listed biotech index constituents.

$YUEXIU PROPERTY (00123.HK)$Acquired the East Xiaolu land in Haizhu District, Guangzhou for 1.9 billion yuan.

$GAC GROUP (02238.HK)$Proposed a transfer of 18.82% equity of JUWAN Tech Research for 1.331 billion yuan.

$GREENTOWN CHINA (03900.HK)$Intends to sell all the equity of Hangzhou Chengling Green Long Enterprise Management for 0.4823 billion yuan.

$RYKADAN CAPITAL (02288.HK)$Intends to sell the property for a total of 0.1635 billion Hong Kong dollars.

$ASIA ALLIED INF (00711.HK)$Intends to acquire 51% equity of Wampang Supply Chain (Hong Kong) for 47.5039 million Hong Kong dollars.

$SHANDONG XINHUA (00719.HK)$Azithromycin dry suspension passed the generic drug quality and efficacy consistency evaluation.

$LUYE PHARMA (02186.HK)$Zai Bei Jia has been approved for listing in mainland China. As of now, Zai Bei Jia has obtained listing approval in 17 countries or regions worldwide.

$HUTCHMED (00013.HK)$、$INNOVENT BIO (01801.HK)$Jemincare and Mutuamuma jointly announced that Aiutec and Davosu have obtained conditional approval from the China National Medical Products Administration for the treatment of advanced endometrial cancer.

$ACOTEC-B (06669.HK)$The registration application for ACOART CAMELLIA, a paclitaxel-eluting coronary artery balloon dilator, has been approved by the China National Medical Products Administration.

$TG SMART ENERGY (01083.HK)$Selling equity of subsidiaries to Asset Support Special Plan.

2) Repurchase Dynamics

$HUA HONG SEMI (01347.HK)$Received notification from shareholder Xinxin Hong Kong, from September 30 to December 2, 2024, plan to reduce company's H shares by 17.726 million shares through block trading, reducing shareholding from 9.33% to 8.29%.

$TENCENT (00700.HK)$Investing approximately 0.703 billion Hong Kong dollars to repurchase 1.76 million shares at a repurchase price of 395-404.2 Hong Kong dollars.

$AIA (01299.HK)$Investing 61.6065 million Hong Kong dollars to repurchase 1.0642 million shares at a repurchase price of 57.35-58.2 Hong Kong dollars.

$KUAISHOU-W (01024.HK)$On December 3, spending approximately 19.9505 million Hong Kong dollars to repurchase 0.41 million shares.

$SINOPEC CORP (00386.HK)$Investing 10.4458 million Hong Kong dollars to repurchase 2.5 million shares at a repurchase price of 4.13-4.22 Hong Kong dollars.

Editor/Danial